孟鲁司特的联合盐酸奥洛他定对慢性荨麻疹患者IgE水平和生活质量的影响  

Clinical efficacy of montelukast combined with olopatadine hydrochloride tablets in the treatment of chronic urticaria and its influences on IgE levels and quality of life

作　　者：杨帆[1] YANG Fan(Department of Dermatology and Venereology,the People’s Hospital of Langfang City,Hebei,Langfang 065000,China)

机构地区：[1]河北省廊坊市人民医院皮肤性病科,065000

出　　处：《河北医药》2024年第2期239-242,共4页Hebei Medical Journal

基　　金：廊坊市科学技术研究与发展计划(编号:2020013070)。

摘　　要：目的研究孟鲁司特钠联合盐酸奥洛他定治疗慢性荨麻疹临床疗效及对患者IgE水平、生活质量、复发率的影响。方法将88例慢性荨麻疹患者随机分为对照组和治疗组,每组44例。对照组给予盐酸奥洛他定片治疗,观察组给予孟鲁司特钠联合盐酸奥洛他定片治疗,疗程均为1个月。比较2组临床疗效及治疗前后IgE水平、皮肤病生活质量指数(DLQI)评分,治疗期间不良反应、6个月内复发率。结果治疗组总有效率高于对照组(P<0.05)。治疗后,2组患者风团数量、大小、持续时间、发生频率及瘙痒程度评分和总分、血清IgE水平、DLQI量表各项评分均降低(P<0.05),且治疗组更低(P<0.05)。2组不良反应发生率比较,差异无统计学意义(P>0.05)。随访3、6个月时,治疗组复发率均低于对照组(P<0.05)。结论孟鲁司特钠联合盐酸奥洛他定片治疗慢性荨麻疹临床疗效更佳,更能有效降低IgE水平,提高患者生活质量,且6个月内复发率更低。Objective To observe the clinical efficacy of montelukast combined with olopatadine hydrochloride tablets on the treatment of chronic urticaria and its effect on IgE levels,quality of life,and recurrence rate.Methods A total of 88 patients with chronic urticaria were randomly divided into the control group and observation group,with 44 cases peRgroup.Olopatadine hydrochloride tablets were given to all patients,and those in the observation group were additionally treated with montelukast.Medication was performed for 1 month.The clinical efficacy and IgE levels before and after treatment,the Dermatology Life Quality Index(DLQI),adverse events during treatment,and recurrence rate within 6 months were compared between the two groups.Results After treatment,the total effective rate of the observation group was significantly higher than that of the control group(P<0.05).The number,size,duration,frequency,itching severity score and total score of urticaria,serum IgE level,and the DLQI after treatment were all significantly reduced in the both groups than those before treatment(P<0.05),which were significantly lower in the observation group than those of the control group(P<0.05).There was no significant difference in the incidence of adverse events between groups(P>0.05).The recurrent rate at 3 and 6 months of follow-up was significantly lower in the observation group than that of the control group(P<0.05).Conclusion Montelukast combined with olopatadine hydrochloride tablets has a betteRclinical effect in the treatment of chronic urticaria,which can effectively reduce IgE levels,improve the quality of life,and presents a lower recurrent rate within 6 months.

关 键 词：慢性荨麻疹 联合治疗 抗组胺 IGE 生活质量 

分 类 号：R758.24[医药卫生—皮肤病学与性病学]